Sept 7 (Reuters) - Sigma Healthcare Ltd (SIG) :
- Sales revenue heavily impacted this year by pull back in sales of low margin hepatitis C medicines, exit of non-compliant branded customer group
- Confirms trading update provided on 11 August 2017 guiding to expected underlying EBIT of $90 million for FY2018
- A number of factors point to a more positive outlook for FY2019
News: SIG Sigma Healthcare confirms underlying EBIT of $90 mln for FY2018
Add SIG (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.91 |
Change
0.050(1.75%) |
Mkt cap ! $2.300B | |||
| Open | High | Low | Value | Volume |
| $2.87 | $2.96 | $2.85 | $24.81M | 8.515M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 146126 | $2.90 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.91 | 573848 | 8 |
View Market Depth
| Last trade - 16.10pm 03/12/2024 (20 minute delay) ? |
| SIG (ASX) Chart |
